Don't damage UK reputation as life sciences leader, industry says

9 October 2023
uk_london_city_gloom_large

More than 20 industry leaders from companies supplying the UK’s National Health Service (NHS) with essential medicines warn that plans to change the Statutory Scheme for branded medicines are unworkable.

If implemented, the industry claims that the measures will reduce patient access to medicines, harm clinical research, and undermine investment in UK life sciences.

A government consultation proposing changes to the Statutory Scheme for branded medicines - replacing the soon-to-expire voluntary scheme for branded medicines pricing and access (VPAS) - has prompted the criticism.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical